Psyence Biomedical (PBM) Cash & Equivalents (2023 - 2026)

Psyence Biomedical's Cash & Equivalents history runs 4 years deep, the most recent figure standing at $7.4 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 21.35% year-over-year to $7.4 million in Q1 2026; TTM through Mar 2026 was $7.4 million, a 21.35% increase from a year earlier, with the FY2026 full-year figure at $7.4 million, up 21.35% from the prior year.
• Cash & Equivalents grew to $7.4 million in Q1 2026 per PBM's latest filing, from $7.1 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $7.4 million in Q1 2026 and bottomed at $0.09 in Q3 2023.
• The 4-year median for Cash & Equivalents is $1.9 million (2024), against an average of $3.5 million.
• Biggest YoY gain for Cash & Equivalents was 2191710608.37% in 2024; the steepest drop was 45.05% in 2024.
• Year by year, Cash & Equivalents stood at $0.09 in 2023, then jumped by 2191710608.37% to $1.9 million in 2024, then surged by 269.98% to $7.1 million in 2025, then advanced by 4.12% to $7.4 million in 2026.
• Per Business Quant, the three latest PBM Cash & Equivalents figures stand at $7.4 million (Q1 2026), $7.1 million (Q3 2025), and $6.1 million (Q1 2025).